Fournier Teams With RGene For Cancer Drug
Fournier of France is to invest up to $25 million to secure codevelopment and European marketing rights to RGG0853, a tumor suppressor gene therapy discovered by RGene Therapeutics of the USA.
The companies will develop RGG0853 for ovarian and metastatic breast cancer in a joint clinical program aimed at getting the drug approved worldwide. The therapy is currently in Phase I trials. Fournier will have marketing rights in Europe and certain African countries with RGene retaining rights elsewhere.
RGG0853 consists of DC-cholesterol, RGene's proprietary lipid-based gene delivery system, complexed with E1A, a gene known to suppress the activity of the HER-2/neu oncogene. HER-2/neu is active in around 30% of ovarian and breast cancers, and overexpression of the gene is associated with poor prognosis in ovarian cancer patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze